12 Oct
2021

FDA orphan drug defeat has important implications for exclusivity

An appellate court has described FDA policy as “arbitrary, capricious and not in accordance with the law” in a decision that has major ramifications for orphan drug designation and exclusivity

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth